1994 - Fellow of the Royal Society, United Kingdom
Raymond Baker mainly focuses on Stereochemistry, Receptor, Bicyclic molecule, NMDA receptor and Glycine. His Stereochemistry study combines topics in areas such as Agonist, Antagonist, Potency, Ring and Alkyl. As a part of the same scientific study, Raymond Baker usually deals with the Receptor, concentrating on Imidazole and frequently concerns with Triazole, Tetrazole and Diazepam.
His Bicyclic molecule study combines topics from a wide range of disciplines, such as Biological activity, Heptane, Steric effects and Amine gas treating. The study incorporates disciplines such as Glycine receptor and Glycine binding in addition to NMDA receptor. His Carbon atom research focuses on Senile dementia and how it relates to Substituent and Medicinal chemistry.
Raymond Baker spends much of his time researching Stereochemistry, Organic chemistry, Medicinal chemistry, Receptor and Ring. His study looks at the relationship between Stereochemistry and fields such as Alkyl, as well as how they intersect with chemical problems. Morpholine, Catalysis, Acetal, Aldehyde and Epoxide are the subjects of his Organic chemistry studies.
His Medicinal chemistry research is multidisciplinary, incorporating perspectives in Yield, Adduct, Allene and Nickel. While the research belongs to areas of Receptor, he spends his time largely on the problem of Triazole, intersecting his research to questions surrounding Sulphate salt, Ethylamine and Combinatorial chemistry. Raymond Baker studies Ring, focusing on Carbon atom in particular.
Pharmacology, Stereochemistry, NK 1 Receptor Antagonists, Morpholine and Receptor are his primary areas of study. His study in Pharmacology is interdisciplinary in nature, drawing from both Tachykinin receptor and Receptor antagonist. His research in Stereochemistry focuses on subjects like Lithium amide, which are connected to Furan.
The concepts of his Morpholine study are interwoven with issues in Scientific method, Prodrug and Halogen. Within one scientific family, Raymond Baker focuses on topics pertaining to Moiety under Receptor, and may sometimes address concerns connected to Bicyclic molecule, Cholecystokinin B receptor and Biological activity. In his study, Alkoxy group is inextricably linked to Ring, which falls within the broad field of Medicinal chemistry.
His main research concerns Stereochemistry, Pharmacology, Receptor, Orally active and Receptor antagonist. His studies deal with areas such as Heteroatom, Alkyl and Chemical synthesis as well as Stereochemistry. Raymond Baker combines subjects such as Prodrug and Halogen with his study of Heteroatom.
His Chemical synthesis research is multidisciplinary, incorporating elements of NMDA receptor, Glycine and Antagonist. His Plasma protein binding study in the realm of Pharmacology interacts with subjects such as Postherpetic neuralgia. His work is dedicated to discovering how Receptor, Dopamine are connected with Combinatorial chemistry, In vitro, Isoxazole, Selective antagonist and Biochemistry and other disciplines.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
4-Amido-2-carboxytetrahydroquinolines. Structure-activity relationships for antagonism at the glycine site of the NMDA receptor.
P D Leeson;R W Carling;K W Moore;A M Moseley.
Journal of Medicinal Chemistry (1992)
Novel 5-HT3 antagonists. Indole oxadiazoles.
C. J. Swain;R. Baker;C. Kneen;J. Moseley.
Journal of Medicinal Chemistry (1991)
Novel quinuclidine-based ligands for the muscarinic cholinergic receptor
John Saunders;Mark Cassidy;Stephen B. Freedman;Elizabeth A. Harley.
Journal of Medicinal Chemistry (1990)
Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the N-methyl-D-aspartate receptor.
Paul D. Leeson;Raymond Baker;Robert W. Carling;Neil R. Curtis.
Journal of Medicinal Chemistry (1991)
Total Synthesis and Determination of the Absolute Configuration of Epibatidine
Stephen R. Fletcher;Raymond Baker;Mark S. Chambers;Richard H. Herbert.
Journal of Organic Chemistry (1994)
Novel benzodiazepine receptor partial agonists: oxadiazolylimidazobenzodiazepines.
Frank Watjen;Raymond Baker;Mogens Engelstoff;Richard Herbert.
Journal of Medicinal Chemistry (1989)
Imidazole, triazole and tetrazole derivatives
Raymond Baker;Victor G. Matassa;Leslie J. Street.
Substituted morpholine derivatives and their use as therapeutic agents
Raymond Baker;Timothy Harrison;Angus Murray Macleod;Andrew Pate Owens.
Total synthesis of (+)-macbecin I
Raymond Baker;Jose L. Castro.
Journal of The Chemical Society-perkin Transactions 1 (1990)
Effect of plasma protein binding on in vivo activity and brain penetration of glycine/NMDA receptor antagonists.
Michael Rowley;Janusz J. Kulagowski;Alan P. Watt;Denise Rathbone.
Journal of Medicinal Chemistry (1997)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: